Braveheart Investment Group plc Further re Paraytec Limited

TIDMBRH

Braveheart Investment Group plc

03 September 2020

RNS Reach announcement (non-regulatory)

3 September 2020

Braveheart Investment Group plc

("Braveheart" or the "Group")

Further re Paraytec Limited

Further to its announcement on 5 August 2020, Braveheart is pleased to provide an update concerning the development of a COVID-19 test that Paraytec Limited is conducting with the University of Sheffield.

WP3 Development of the Signal Generation Module

Having previously completed workpackages 1 & 2 which have dealt with the construction of a viral mimic and the CAPTURE system for Paraytec's COVID-19 test, development of the Signal Generation Module is complete. At the heart of the Signal Generation module is a synthetic COVID-19 virus binding protein molecule which has now been isolated and bonded to fluorescent nanospheres.

WP5 Development of Optical Detection system

Work has been initiated and continues to progress on building the Optical Detection system. This will be used to detect and quantify fluorescent nanospheres that bind the CAPTURE Module in the presence of SARS-nCov2 virus. In order to evaluate the operating characteristics of the system, Paraytec has built CAPTURE microspheres coated with appropriate fluorescent SIGNAL GENERATION components for the purposes of visualisation and quantitation. In the test, optical detection of fluorescently labelled microspheres is achieved using a very high sensitivity photodiode that responds to a single photon of light, to generate an "avalanche" of electrons, registering the presence of viral particles.

Professor Carl Smythe commented, "We are pleased with Paraytec's continued progress in building this rapid test. A key issue associated with COVID-19 testing will be the detection of disease in people who have very low levels of viral particles in swab or saliva samples. By using a highly sensitive detection system, the test will maximise the potential to detect asymptomatic carriers of the virus. Over the next month, we will be undertaking proof-of-concept testing, which we hope to complete by early October."

For further information

 
 Braveheart Investment Group plc          Tel: [phone] 
  Trevor Brown, Chief Executive Officer 
 

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.

END

NRADZGGLRZNGGZM

(END) Dow Jones Newswires

September 03, 2020 02:00 ET (06:00 GMT)